
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
In addition to overall concerns about COVID-19 vaccines patients may have stronger fears about the second vaccine dose since it is often accompanied with more adverse effects.





